The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors.
M. N. Dickler
Research Funding - PTC Therapeutics
B. P. Schneider
Research Funding - PTC Therapeutics
M. Volm
Research Funding - PTC Therapeutics
J. L. Speyer
Research Funding - PTC Therapeutics
Y. Novik
Research Funding - PTC Therapeutics
L. A. Callahan
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
C. H. Darby
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
J. Barth
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
G. L. Elfring
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
A. Ogden
Employment or Leadership Position - PTC Therapeutics
Stock Ownership - PTC Therapeutics
Research Funding - PTC Therapeutics
A. Tiersten
Research Funding - PTC Therapeutics